Vyvanse is a drug owned by Takeda Pharmaceuticals Usa Inc. It is protected by 36 US drug patents filed from 2013 to 2021 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 24, 2023. Details of Vyvanse's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vyvanse's patents.

Latest Legal Activities on Vyvanse's Patents

Given below is the list of recent legal activities going on the following patents of Vyvanse.

Event	Date	Patent/Publication
Critical Events for all Patents
Payment of Maintenance Fee, 12th Year, Large Entity	21 Oct, 2021	US7718619 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	21 Oct, 2021	US7713936
Payment of Maintenance Fee, 12th Year, Large Entity	21 Oct, 2021	US7723305 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	24 Sep, 2021	US7700561 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	18 Aug, 2021	US7674774 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	18 Aug, 2021	US7687466 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	18 Aug, 2021	US7678770 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	18 Aug, 2021	US7671031 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	18 Aug, 2021	US7671030 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	18 Aug, 2021	US7678771 (Litigated)

FDA has granted several exclusivities to Vyvanse. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Vyvanse, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Vyvanse.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

Several oppositions have been filed on Vyvanse's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Vyvanse's generic, the next section provides detailed information on ongoing and past EP oppositions related to Vyvanse patents.

Vyvanse's oppositions filed in EPO

Vyvanse has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 15, 2012, by Hexal Ag. This opposition was filed on patent number EP04753925A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status
Live updates
EP04753925A	Nov, 2012	JOHNSON MATTHEY PUBLIC LIMITED COMPANY	Patent maintained as amended
EP04753925A	Nov, 2012	Generics [UK] Limited	Patent maintained as amended
EP04753925A	Nov, 2012	Hexal AG	Patent maintained as amended

US patents provide insights into the exclusivity only within the United States, but Vyvanse is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vyvanse's family patents as well as insights into ongoing legal events on those patents.

Vyvanse's family patents

Vyvanse has patent protection in a total of 27 countries. It has a significant patent presence in the US with 85.9% of its patents being US patents. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Vyvanse.

Full family tree

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Generic Launch

About Vyvanse

Vyvanse is a drug owned by Takeda Pharmaceuticals Usa Inc. It is used for managing symptoms of Attention Deficit Hyperactivity Disorder (ADHD) in both adults and children. Vyvanse uses Lisdexamfetamine Dimesylate as an active ingredient. Vyvanse was launched by Takeda Pharms Usa in 2017.